FORM PTO-1449

U.S. Department of Commerce

(Modified)

Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use Several Sheets If Necessary)

(37 CFR ? 1.98(b))

PA Emey Docket No.: FORS-06638 JAN 3 1 2008

Serial No.: 09/982,667

Applicant:	<u>James</u>	R.	PRUDENT	et al.	

Filing Date: 10/18/01	 Group Art Unit:

Examiner Initials	Cite No	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
initials	NO. 1	6,348,314					
1	2	6,090,543			- -/ 		
	3	5,846,717					
- 	44	08/599,491				7	
	5	08/682,853			1	(
	6	08/756,386					
	7	08/759,038					
	8	08/823,516				-	
	9	09/308,825				/	
	10	09/350,309					
	11	09/350,597					
1	12	09/381,212					
	13	09/940,925				7	
	14	09/941,193				- 	
	15	09/655,378				/	
	16	09/660,924			(/	
	17	09/940,244					
	18	10/081,806					
1	19	09/713,601			/		•
	20	10/033,297					
1	21	09/732,622					
	22	10/309,584					
1/2	· 23	-10/891-793	Not the only	et Matter)]	
		_					

EXAMINER:

Inftial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

applicant.



FORM PTO- 1449 U.S. Departme (Modified) Patent and Tra			Attorney Docket No.: FORS-06638	Serial No.: 09/982,667
INFO	ORMATIO	ON DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		
(37 CFR ? 1.9	98(b))			
			Applicant: James R. PRUDENT et al.	
		OTHER DOCUMENTS (Including Author, Title, D	Filing Date: 10/18/01	Group Art Unit:
B	24	Hessner et al., Genotyping of Factor V G1691A (Leiden) without Chemistry 46:1051-1056 (2000)		Oligonucleotide Probes, Clinical
	25	Lyamichev et al., Experimental and Theoretical Analysis of the	Invasive Signal Amplification Reaction, Bio	chemistry 39:9523-9532 (2000)
	26	Neri et al., Transferring Automation for Large-scale Developme 1:117-125 (2000)	nt and Production of Invader TM SNP Assays	, Progress in Biomedical Optics
	27	Newlin et al., The Invader Assay: An Alternative To PCR-Base Thrombosis, Clinical Hemostasis Review, 14:10-12 (2000)	d Testing For The Detection Of Point Mutat	ions Associated With Venous
	28	Hall et al., Sensitive detection of DNA polymorphisms by the se	rial invasive signal amplification reaction, I	PNAS 97:8272-8277 (2000)
	29	Ledford et al., A Multi-Site Study for Detection of the Factor V Microtiter Plate Fluorescence Resonance Energy Transfer (FRE)		
	30	Ma et al., RNA Template-dependent 5' Nuclease Activity of The 275:24693-24700 (2000)	ermus aquaticus and Thermus thermophilus	DNA Polymerases, J. Biol.Chem.,
	31	Fors et al., Large-scale SNP scoring from unamplified genomic	DNA, Pharmacogenomics 1(2):219-229 (20	000)
	32	Agarwal et al., Comparison Study For Identifying Promoter Alle Mol Pathol 9(3):158-164 (2000)	elic Polymorphism in Interleukin 10 and Tur	nor Necrosis Factor á Genes, Diagn
	33	Cooksey et al., Evaluation of the Invader Assay, a Linear Signal Resistance to Rifampin and Isoniazid in Mycobacterium tuberca	•	
	34	Mein et al., Evaluation of Single Nucleotide Polymorphism Typ 10:330-343 (2000	ing with Invader or PCR Amplicons and Its	Automation, Genome Research
	35	Lieder, Excitement Builds in Molecular Biology, Advance for A	dministrators of the Laboratory50-52 (1999)
	36	Lieder, Invader Technology Provices Alternative to PCR, Advan	ce for Administrators of the Laboratory, 70	-71 (2000)
	37	Treble et al., Invader ? technology for SNP detection, Gene &	Medicine 4:68-72 (2000)	
	38	Kwiatkowski et al., Clinical, Genetic, and Pharmacogenetic App	olications of the Invader Assay, Molecular L	Diagnosis, 4:353-364 (1999)
	39	Check, Labs home in on mutant alleles, College of American Pa	thologists Today, 1-5 September (1999)	· · · · · · · · · · · · · · · · · · ·
	40	Griffin et al., Direct genetic analysis by matrix-assisted laser des	sorption/ionization mass spectrometry, PNA.	S 96:6301-6306 (1999)
	41	Ryan et al., Non-PCR-Dependent Detection of the Factor V Leic Plate Assay, Molecular Diagnosis, 4:135-144 (1999)	den Mutation From Genomic DNA Using a	Homogeneous Invader Microtiter
	42	Kaiser et al., A Comparison of Eubacterial and Archaeal Structu	re-specific 5'-Exonucleases, J. Biol. Chem.,	274:21387-21394 (1999)
	43	Lyamichev et al., Polymorphism identification and quantitative Nature Biotech. 17:292-296-(1999)	detection of genomic DNA by invasive clear	vage of oligonucleotide probes,
	44	Harrington, The Characterization of the Fen-1 Family of Structu And Repair, Dissertation submitted to the Program in Cancer Bi	•	•
M	45	Defrancesco, The Next New Wave in Genome Analysis, The Sc.		
Examiner:		Myl Ui	Date Considered: 3/9/	01
EXAMINER:		tial citation considered. Draw line through citation if not in confor to applicant.	mance and not considered. Include copy of	this form with next
		7.7		

Property of TRACERIAN

FORM PTO-1449
(Modified)

Attorney Docket No.: FORS-06638

Serial No.: 09/982,667

(Modifica)						
INFO	ORMATI	ON DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				
(37 CFR ? 1.9	98(b))		A LI D D DDIDENT			
			Applicant: James R. PRUDENT			
		OTHER DOCUMENTS (Including Author,	Filing Date: 10/18/01	Group Art Unit:		
	46					
	Lyamichev, et al., Comparison of the 5' nuclease activities of Taq DNA polymerase and its isolated nuclease domain. Proc. 96: 6143-6148 (1999)					
M	47	Turchi, et al., Completion of Mammalian Lagging Stran	d DNA Replication Using Purified Proteins.	J. Biol Chem. 268(20):15136-141 (1993)		
	48	Third Wave Technologies, Inc. v. EraGen Biosciences, Inc., Civil Case No. 3:2002cv00507 (W.D. Wis.) (the "Third Wave v. EraGen" litigation)				
	49					
	50	Docket Sheet for Civil Case No. 3:2002cv00507-C (W.D.Wis), filed 09/06/2002, closed on 04/14/2003				
	51	Complaint, filed 09/06/2002				
	52	Answer, Affirmative Defenses and Counterclaim, filed 10/07/2002				
	53	Third Wave Technologies' Reply to Defendant Eragen's Counterclaim, October 28, 2002				
	54	Third Wave Technologies' Motion to Strike Eragen's Affirmative Defenses and Counterclaim of Invalidity, Octo 28, 2002				
	55					
Third Wave Technologies' Reply in Support of Its Motion to Strike Eragen's Affirmative Des			rmative Defenses and Counterclain			
v	57	Defendant's Surreply in Opposition to Plaintiff's Motion to Strike Eragen's Affirmative Defenses and Counterclaim of Invalidity, November 27, 2002				
	58	Plaintiff's Response to Defendant's First Set of Interrogatories to Third Wave Technologies, Inc., November 21, 2002				
	59	Plaintiff's Amended Response to Defendant's First Set of Interrogatories to Third Wave Technologies, Inc., November 21, 2002December 3, 2002				
	60	Defendant's Rule 26(a)(1) Disclosures; November 4, 2002				
	61	Defendant's Responses to TWT's Expedited Third Set of Interrogatories (Nos. 15-16), January 27, 2003				
	62	Defendant's Amended Responses to TWT's Expedited Third Set of Interrogatories (Nos. 15-16), March 28, 2003				
	63	Order on Claims Construction Hearing, March 19, 2003				
	64	Docket Sheet for Civil Case No. 04-C-0680-C (W.D.Wis), filed 09/15/2004				
	65	Complaint, 09/15/2004				
	66 /	Apswer, 10/20/2004				
	/					
	67/	Amended Answer and Counterclaims, Decem	ber 30, 2004			

EXAMINER:

initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next

communication to applicant.